mhurhangee/ep-ind-claims huggingface dataset:
An auto changer spindle mounting assembly for mounting a spindle to a computer controlled machining system so that the spindle can be selectively exchanged by an automatic changer device, the spindle mounting assembly comprising: a gas inlet assembly; a mounting collar that defines a collar opening therethrough between a first side and a second side of the mounting collar for receiving a portion of the spindle, the collar opening including a nipple opening, wherein the mounting collar further defines a collar passage in fluid communication with the gas inlet assembly and the collar opening, which collar passage is configured to direct fluid into the collar opening through the nipple opening and a lock screw inside the nipple opening serves to secure the spindle to the mounting collar; a manifold body with a gas outlet adapted to mate with the gas inlet assembly of the collar, the manifold body defines a manifold passage in fluid communication between the gas outlet and a manifold body inlet; and at least one extension bar adapted to mechanically fasten the manifold body to a computer controlled machining system. a gas inlet assembly; a mounting collar that defines a collar opening therethrough between a first side and a second side of the mounting collar for receiving a portion of the spindle, the collar opening including a nipple opening, wherein the mounting collar further defines a collar passage in fluid communication with the gas inlet assembly and the collar opening, which collar passage is configured to direct fluid into the collar opening through the nipple opening and a lock screw inside the nipple opening serves to secure the spindle to the mounting collar; a manifold body with a gas outlet adapted to mate with the gas inlet assembly of the collar, the manifold body defines a manifold passage in fluid communication between the gas outlet and a manifold body inlet; and at least one extension bar adapted to mechanically fasten the manifold body to a computer controlled machining system.
A mould flux having a composition of, in weight%: SiO 2 15-25; CaO 15-35; Al 2 O 3 1-7; Na 2 O 18-30; K 2 O 15-25; Fe 2 O 3 0-5; C 0-4; TiO 2 0-2; MnO 0-2; MgO 0-2; Li 2 O 0-10; and wherein the melting point of the mould flux is less than or equal to 1300°C.
Method of manufacturing a structure comprising a graphene sheet that is provided, on one of the faces thereof, with a plurality of metal pins, these pins being separated from one another by a dielectric medium chosen from air and dielectric materials, said method being characterised in that it comprises: a) the synthesis, by vapour phase catalytic growth, of the graphene sheet on a plurality of metal pins that are disposed on a membrane made from dielectric material or integrated in this membrane, this growth being catalysed by said metal pins; and optionally b) the removal of said membrane. a) the synthesis, by vapour phase catalytic growth, of the graphene sheet on a plurality of metal pins that are disposed on a membrane made from dielectric material or integrated in this membrane, this growth being catalysed by said metal pins; and optionally b) the removal of said membrane.
An activator of IFNλ receptor for use in (a) the prevention or treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder in a subject; or (b) determining susceptibility of a subject suffering from an obesity-related disorder, atherosclerosis or a coagulation disorder to treatment with the activator of IFNλ receptor, wherein the activator of IFNλ receptor is administered to the subject and the effect on the obesity-related disorder, atherosclerosis or the coagulation disorder is determined, respectively, wherein the obesity-related disorder is selected from the group consisting of obesity, prediabetes, diabetes (including type 1 diabetes, type 2 diabetes, and gestational diabetes), insulin resistance, metabolic disease, metabolic syndrome, coronary heart disease, carotid artery disease, myocardial infarction, stroke, thrombosis, dyslipidemia, hyperlipidemia, hypercholesterolemia, and wherein the activator of IFNλ receptor is IFNλ, or a polynucleotide expressing IFNλ. (a) the prevention or treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder in a subject; or (b) determining susceptibility of a subject suffering from an obesity-related disorder, atherosclerosis or a coagulation disorder to treatment with the activator of IFNλ receptor, wherein the activator of IFNλ receptor is administered to the subject and the effect on the obesity-related disorder, atherosclerosis or the coagulation disorder is determined, respectively,
A film deposition apparatus comprising: a processing chamber having a vacuum space thereinside and to which a film deposition gas is supplied; a substrate supporting unit which is disposed in the vacuum space and serves to support a substrate; a coil unit which serves to inductively heat the substrate supporting unit and is divided into a plurality of coils (107A, 107B); and a coil control unit which independently controls the plurality of coils (107A, 107B), characterized in that the coil control unit includes a power control unit for controlling a power level of a high frequency power applied to each of the coils (107A, 107B); the coils (107A, 107B) are arranged in accordance with a flow of the film deposition gas in the processing chamber; and the power control unit sets the power level of the high frequency power applied to a first coil among the coils (107A, 107B) to be higher than that applied to a second coil among the coils (107A, 107B), the first coil being disposed at an upstream side of the flow and the second coil being disposed at a downstream side of the flow. a processing chamber having a vacuum space thereinside and to which a film deposition gas is supplied; a substrate supporting unit which is disposed in the vacuum space and serves to support a substrate; a coil unit which serves to inductively heat the substrate supporting unit and is divided into a plurality of coils (107A, 107B); and a coil control unit which independently controls the plurality of coils (107A, 107B), characterized in that the coil control unit includes a power control unit for controlling a power level of a high frequency power applied to each of the coils (107A, 107B); the coils (107A, 107B) are arranged in accordance with a flow of the film deposition gas in the processing chamber; and the power control unit sets the power level of the high frequency power applied to a first coil among the coils (107A, 107B) to be higher than that applied to a second coil among the coils (107A, 107B), the first coil being disposed at an upstream side of the flow and the second coil being disposed at a downstream side of the flow.
An apparatus for wrapping a load with packaging material, the apparatus comprising: a packaging material dispenser for dispensing packaging material to the load; a load support for supporting the load during wrapping, wherein the packaging material dispenser and the load support are adapted for rotation relative to one another about a center of rotation; an angle sensor configured to sense an angular relationship between the load and the packaging material dispenser about the center of rotation; characterized by a controller coupled to the angle sensor and configured to control a dispense rate of the packaging material dispenser during the relative rotation based at least in part on an effective circumference of the load that varies during the relative rotation and that is determined using the sensed angular relationship. a packaging material dispenser for dispensing packaging material to the load; a load support for supporting the load during wrapping, wherein the packaging material dispenser and the load support are adapted for rotation relative to one another about a center of rotation; an angle sensor configured to sense an angular relationship between the load and the packaging material dispenser about the center of rotation; characterized by a controller coupled to the angle sensor and configured to control a dispense rate of the packaging material dispenser during the relative rotation based at least in part on an effective circumference of the load that varies during the relative rotation and that is determined using the sensed angular relationship.
Tile element for constructing a modular construction, the tile element comprising a chassis with a base body which has a visible side which is provided substantially wholly with an LED screen, wherein the base body comprises first connecting sides adjacently of a peripheral edge of the visible side, characterized in that the first connecting sides extend at an angle relative to the visible side and wherein the chassis further comprises edge bodies which can be connected to the base body in order to form, where the edge body is connected, a second connecting side which extends substantially perpendicularly of the visible side, wherein the first connecting sides run all around the whole peripheral edge of the visible side and wherein the second connecting sides run all around the whole peripheral edge of the visible side when all edge bodies are connected to the base body, wherein the edge bodies comprise complementary tile connecting means, which tile connecting means allow tile elements to be connected directly to each other when second connecting sides lie against each other.
An asymmetric device for regulating blood volume distribution across a patient's atrial septum, the device comprising: a first flared expandable end region having an inlet end, the first flared expandable end region being configured to transition from a contracted delivery state to an expanded deployed state in which the first flared expandable end region partially engages a left side of the atrial septum and extends into the patient's left atrium and the inlet end of the first flared expandable end region is in a first plane; a second flared expandable end region (54, 64) having an outlet end, the second flared expandable end region (54, 64) being configured to transition from a contracted delivery state to an expanded deployed state in which the second flared expandable end region (54, 64) partially engages a right side of the atrial septum and extends into the patient's right atrium and the outlet end of the second flared expandable end region (54, 64) is in a second plane; and a neck region joining the first flared expandable end region to the second flared expandable end region (54, 64), the neck region configured for placement in the patient's atrial septum, wherein diameters of the first and second flared expandable end regions (51, 54, 64) are selected to stabilize the device at the atrial septum, and wherein the first plane intersects the second plane such that blood exits the outlet end at a different angle from a direction of blood flow path through the inlet end. a first flared expandable end region having an inlet end, the first flared expandable end region being configured to transition from a contracted delivery state to an expanded deployed state in which the first flared expandable end region partially engages a left side of the atrial septum and extends into the patient's left atrium and the inlet end of the first flared expandable end region is in a first plane; a second flared expandable end region (54, 64) having an outlet end, the second flared expandable end region (54, 64) being configured to transition from a contracted delivery state to an expanded deployed state in which the second flared expandable end region (54, 64) partially engages a right side of the atrial septum and extends into the patient's right atrium and the outlet end of the second flared expandable end region (54, 64) is in a second plane; and a neck region joining the first flared expandable end region to the second flared expandable end region (54, 64), the neck region configured for placement in the patient's atrial septum, wherein diameters of the first and second flared expandable end regions (51, 54, 64) are selected to stabilize the device at the atrial septum, and wherein the first plane intersects the second plane such that blood exits the outlet end at a different angle from a direction of blood flow path through the inlet end.
A shipboard water treatment system, comprising: a source of seawater wherein the source of seawater comprises a sea chest; a ballast tank fluidly connected to the sea chest; wherein the sea chest is fluidly connected to a shipboard cooling water system; a first sensor disposed to measure and transmit a first measured signal representative of an oxidation reduction potential of the seawater in the sea chest; a second sensor disposed to measure and transmit a second measured signal representative of an oxidation reduction potential of the seawater in the ballast tank; a biocide source disposed to introduce a biocide into the seawater, and a controller disposed to receive the first measured signal from the first sensor and to receive the second measured signal from the second sensor, and configured to generate and transmit an output signal, based at least partially on the first measured signal, the second measured signal, and a target ORP value in a range of from about 200 mV to about 1000 mV, to the biocide source to regulate a rate of introduction of the biocide into the seawater in the ballast tank and into the sea chest to achieve a target biofouling control value in water introduced into the shipboard cooling water system. a source of seawater wherein the source of seawater comprises a sea chest; a ballast tank fluidly connected to the sea chest; wherein the sea chest is fluidly connected to a shipboard cooling water system; a first sensor disposed to measure and transmit a first measured signal representative of an oxidation reduction potential of the seawater in the sea chest; a second sensor disposed to measure and transmit a second measured signal representative of an oxidation reduction potential of the seawater in the ballast tank; a biocide source disposed to introduce a biocide into the seawater, and a controller disposed to receive the first measured signal from the first sensor and to receive the second measured signal from the second sensor, and configured to generate and transmit an output signal, based at least partially on the first measured signal, the second measured signal, and a target ORP value in a range of from about 200 mV to about 1000 mV, to the biocide source to regulate a rate of introduction of the biocide into the seawater in the ballast tank and into the sea chest to achieve a target biofouling control value in water introduced into the shipboard cooling water system.
A seal for a large roller bearing for sealing a joint between two adjacent ring segments or ring parts of the roller bearing, characterized by at least two mutually spaced apart sealing limbs (12, 13) of a rubber elastic sealing material for sealing insertion into grooves that are formed at both sides of the joint in ring segments or ring parts that are adjacent to one another and a connection section connecting the sealing limbs (12, 13) and composed of a rubber elastic sealing material to span said joint, wherein a desired stretching section is provided in the region of the connection section and has a greater elasticity and/or a smaller stretching stiffness in comparison with adjacent sealing sections and/or in comparison with the sealing limbs (12, 13).
An electrochemical sensor strip having a first electrode, a second electrode, and a lid on a base, characterized by: a first electrode on the base having at least one first layer on a first conductor, the first layer including a reagent layer comprising from 1.72 to 2 μg/mm 2 of a mediator and an enzyme system at a deposition density from 0.42 to 0.8 μg/mm 2; where the strip is configured to provide a determined analyte concentration value.
An rAAV for use in a method of treating an ocular disease, the method comprising: administering to ocular tissue of a subject an effective amount of the rAAV, wherein the rAAV comprises: (i) a capsid protein having a serotype selected from the group consisting of AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh.8, AAVrh.10, AAVrh.39, and AAVrh.43, and (ii) a nucleic acid comprising a promoter operably linked to a transgene, wherein the transgene comprises a region of complementarity to SEQ ID NO:1, and wherein the transgene decreases the expression of miR-21 wherein the ocular disease is associated with the up-regulation of miR-21. (i) a capsid protein having a serotype selected from the group consisting of AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh.8, AAVrh.10, AAVrh.39, and AAVrh.43, and (ii) a nucleic acid comprising a promoter operably linked to a transgene, wherein the transgene comprises a region of complementarity to SEQ ID NO:1, and wherein the transgene decreases the expression of miR-21
An insulated composite fabric comprising: an inner fabric layer facing towards the user's body; an outer fabric layer; and an insulating-filler fabric layer enclosed between the inner fabric layer and the outer fabric layer, wherein the insulating-filler fabric layer is a textile fabric with a raised surface on at least one side of the fabric comprising multicomponent fibers formed of at least a first polymer and a second polymer disposed in side-by-side relationship, the first polymer and the second polymer exhibiting differential thermal elongation or contraction to cause the multicomponent fibers to bend or curl and reversibly recover in response to changes in temperature, adjusting insulation performance of the textile fabric in response to ambient conditions, and wherein the inner fabric layer has a relatively higher air permeability than the outer fabric layer. an inner fabric layer facing towards the user's body; an outer fabric layer; and an insulating-filler fabric layer enclosed between the inner fabric layer and the outer fabric layer, wherein the insulating-filler fabric layer is a textile fabric with a raised surface on at least one side of the fabric comprising multicomponent fibers formed of at least a first polymer and a second polymer disposed in side-by-side relationship, the first polymer and the second polymer exhibiting differential thermal elongation or contraction to cause the multicomponent fibers to bend or curl and reversibly recover in response to changes in temperature, adjusting insulation performance of the textile fabric in response to ambient conditions, and wherein the inner fabric layer has a relatively higher air permeability than the outer fabric layer.
A method of preparing a protein-based product from fenugreek seeds (TEFS) for use in the treatment of dyslipidemia and obesity, the method comprising: i) grinding dried fenugreek seeds to a fine powder; ii) suspending the ground fine powder of the fenugreek seeds in phosphate-buffered saline at pH 7.4 containing 0.1 mM phenylmethylsulfonyl fluoride (PMSF) and a protease inhibitor mixture to yield an extract; iii) filtering the extract through a three-layered cheese cloth, centrifuging to yield a clear supernatant; iv) treating the clear supernatant with 25 to 75 g/litre activated charcoal powder; v) precipitating protein with 20 to 80% ammonium sulphate for 1-12 hours; vi) removing the precipitate by centrifugation, re-dissolving in PBS and dialyzing against PBS at 4 to 21 °C with at lea st three buffer changes; vii) heat-treating the dialyzed protein rich extract at 50 to 95 °C for 15 to 60 min, preferably at 75-90 °C for 30 min; viii) removing the precipitated protein by centrifugation and retrieving the supernatant as a final product; wherein the final product has a protein concentration of 0.1-15 mg/ml, preferably 1-1.5 mg/ml; and is useful in the management of dyslipidemia and obesity. i) grinding dried fenugreek seeds to a fine powder; ii) suspending the ground fine powder of the fenugreek seeds in phosphate-buffered saline at pH 7.4 containing 0.1 mM phenylmethylsulfonyl fluoride (PMSF) and a protease inhibitor mixture to yield an extract; iii) filtering the extract through a three-layered cheese cloth, centrifuging to yield a clear supernatant; iv) treating the clear supernatant with 25 to 75 g/litre activated charcoal powder; v) precipitating protein with 20 to 80% ammonium sulphate for 1-12 hours; vi) removing the precipitate by centrifugation, re-dissolving in PBS and dialyzing against PBS at 4 to 21 °C with at lea st three buffer changes; vii) heat-treating the dialyzed protein rich extract at 50 to 95 °C for 15 to 60 min, preferably at 75-90 °C for 30 min; viii) removing the precipitated protein by centrifugation and retrieving the supernatant as a final product; wherein the final product has a protein concentration of 0.1-15 mg/ml, preferably 1-1.5 mg/ml; and is useful in the management of dyslipidemia and obesity.
Clothes washing method for a washing machine, comprising a wetting phase, wherein the clothes absorb water, and a washing phase, wherein the clothes are treated mechanically, characterised in that there is at least one partial water drain after the wetting phase and before the end of the washing phase, so that a variable amount of water depending on the selected washing program and the clothing load and type inserted in the washing machine is extracted by means of said partial drain.
Inulin product, whereby the inulin product is polydisperse and has a factor L, defined as a ratio S/D, wherein: • S equals the sum of the compounds GF 2, F 3, and F 4 in the inulin product, expressed in wt.% on total carbohydrates; • D equals [(F i /G i) +1], wherein F i is the amount of inulin-related fructose in the inulin product, G i is the amount of inulin-related glucose in the inulin product, whereby F i and G i are expressed in wt.% on total carbohydrates, characterised in that the value of L lies between 2.20 and 3.0 and wherein between 3 and 20 wt.% on total carbohydrates of the inulin product consists of: • GF n compounds wherein n is 10 or greater, whereby the inulin product contains at most 30 wt.% on total carbohydrates of non-inulin carbohydrates such as free glucose, free fructose, and sucrose. • S equals the sum of the compounds GF 2, F 3, and F 4 in the inulin product, expressed in wt.% on total carbohydrates; • D equals [(F i /G i) +1], wherein F i is the amount of inulin-related fructose in the inulin product, G i is the amount of inulin-related glucose in the inulin product, whereby F i and G i are expressed in wt.% on total carbohydrates, • GF n compounds wherein n is 10 or greater,
A composition comprising hyperbranched oligophosphonates, each hyperbranched oligophosphonate having a degree of branching from 0.05 to 1.0 and wherein 40% to 98% of the total of hyperbranched oligophosphonates have two or more reactive end-groups; and further wherein the degree of branching for the hyperbranched oligomers is defined as the number average fraction of branching groups per molecule.